| Project/Area Number |
24659361
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
SEISHIMA Mitsuru 岐阜大学, 医学(系)研究科(研究院), 教授 (10171315)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITO Hiroyasu 岐阜大学, 大学院医学系研究科, 准教授 (80373075)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | B型肝炎ウイルス / インドールアミン酸素添加酵素 / 細胞傷害性T細胞 / 急性肝炎 / 肝炎ウイルス / 細胞障害性T細胞 |
|---|
| Research Abstract |
Indoleamine 2, 3-dioxygenase (IDO), an enzyme that is ubiquitously distributed in mammalian tissues and cells, converts tryptophan (Trp) to L-kynurenine (L-Kyn), and it is noted as a relevant molecule in promoting tolerance and suppressing adaptive immunity. In this study, we revealed the role of IDO in the induction of HBV-specific cytotoxic T lymphocyte (CTL) and acute hepatitis induced by HBV-specific CTL. IDO impaired the induction of HBV-specific CTL after immunization with HBsAg and alpha-GalCer. In acute hepatitis model, the inhibition of IDO expression improved the liver injury induced by HBV-specific CTL. These results demonstrated that IDO is critical in the induction of HBV-specific CTL and acute hepatitis. The control of IDO activity leads to a new therapy for diseases caused by HBV infection.
|
